Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$273.91 USD
+7.32 (2.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $273.99 +0.08 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$273.91 USD
+7.32 (2.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $273.99 +0.08 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Zacks News
Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.
Alnylam, Sanofi Announce Restructuring Deal for RNAi Products
by Zacks Equity Research
Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.
4 Biotech Stocks That More Than Doubled This Year
by Zacks Equity Research
We take a look at a few biotech stocks whose price has increased more than 100% in 2017.
BioMarin's (BMRN) Gene Therapy Enters First Phase III Study
by Zacks Equity Research
BioMarin (BMRN) commences the first phase III study to evaluate the 6e13 vg/kg dose of its investigational gene therapy, valoctocogene roxaparvovec, for severe hemophilia A.
Why is Alnylam's (ALNY) Stock Up More Than 200% This Year?
by Zacks Equity Research
Alnylam's (ALNY) share price has increased year to date based on impressive progress of its pipeline candidates.
Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy
by Arpita Dutt
A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.
Alnylam/Sanofi Submit MAA in Europe for RNAi Candidate
by Zacks Equity Research
Alnylam (ALNY) and partner Sanofi have submitted a Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment adults with hereditary ATTR amyloidosis with polyneuropathy.
Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran
by Zacks Equity Research
Sanofi (SNY) and Alnylam announced that the FDA has lifted the clinical hold placed on all ongoing studies of its hemophilia candidate, fitusiran.
Alnylam's RNAi Candidate Gains Breakthrough Therapy Status
by Zacks Equity Research
Alnylam (ALNY) announced that the FDA has granted Breakthrough Therapy Designation for RNAi therapeutic candidate, patisiran.
Alnylam Starts Rolling NDA Submission for RNAi Candidate
by Zacks Equity Research
Alnylam (ALNY) has started rolling New Drug Application to the FDA for its RNAi candidate, patisiran.
Why is Alnylam's (ALNY) Stock Up More Than 200% this Year?
by Zacks Equity Research
Alnylam (ALNY) expects to achieve the profile of three marketed products by the end of 2020 and remains focused on development of its pipeline candidates.
Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA
by Zacks Equity Research
Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.
Alnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) incurred wider than expected loss and missed sales estimates in the third quarter of 2017.
What's in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology that helps it form partnerships with several leading healthcare companies might drive the stock in Q3.
What's in Store for Madrigal (MDGL) This Earnings Season?
by Zacks Equity Research
Madrigal (MDGL) expects data readout for its lead candidate MGL-3196 on its third-quarter earnings call.
Inovio (INO) Q3 Earnings: Is a Beat in Store for the Stock?
by Zacks Equity Research
Inovio's (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q3. However, lack of an approved product in the company's portfolio is a dampener.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.
Is a Surprise Coming for Alnylam Pharmaceuticals (ALNY) This Earnings Season?
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 10.3% in Session
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss
by Zacks Equity Research
The Medicines Company (MDCO) incurs loss in the third quarter of 2017. The top line decreases year over year due to low Angiomax sales.
Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up
by Zacks Equity Research
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.
Company News For Sep 21, 2017
by Zacks Equity Research
Companies in the news are: BBBY,FDX,ALNY,GIS
Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped nearly 52% on the day, amid huge volumes.
Calamities Couldn't Spoil The Bullish Run
by Zacks Equity Research
Calamities Couldn't Spoil The Bullish Run
Hurricanes, Earthquakes and Record-High Markets
by Mark Vickery
With Hurricane Maria striking Puerto Rico and two major earthquakes destroying parts of Mexico, markets continue to reach for new record highs.